NorthWest Biotherapeutics Inc (NWBO)

[FatCat_Banker]

If we achieve 1/3 the efficacy of the prior trials in PFS we will meet our endpoint with a p-value of .01 of which .05 is the cut off - per Linda. (or was it 0.001? I don't remember the guidelines if it's 10% or 1% surety.)

I digress.

If median PFS was 6 months in earlier phases, we have to provide 2 months in the larger, randomized treatment sample. Meeting our endpoint with spots of unresponsiveness and systemic responsiveness, knowing that serve diseases get the nod ...

I think we've got a solid shot at termination due to efficacy.

Am I wrong?